英国免疫介导炎症性疾病成人肺炎球菌疫苗接种率与安全性:一项全国性观察性研究
该英国全国性观察性研究纳入32 277例免疫介导炎症性疾病(IMID)成人患者,评估肺炎球菌疫苗接种率;总体接种率为57%,45岁以下者32%、炎症性肠病(IBD)患者42%、无其他接种指征者46%较低。自身对照病例系列分析未发现接种与关节痛、自身免疫风湿病发作或IBD发作的门诊就诊相关。
要点
- 英国IMID成人肺炎球菌疫苗总体接种率为57%,45岁以下者仅32%。
- IBD患者接种率42%,无其他接种指征者接种率46%。
- 接种后暴露期关节痛、自身免疫风湿病发作及IBD发作就诊的发病_rate比均无统计学显著关联。
核心结论
- 英国IMID患者肺炎球菌疫苗接种率不理想。
- 接种肺炎球菌疫苗与IMID发作无关联。
研究设计与样本
- 英国全国性观察性研究,纳入2018年9月1日或之前诊断为IMID、近12个月内使用过保类固醇药物并贡献数据至临床实践研究数据链Gold的成人。
- 采用横断面设计评估疫苗接种率。
- 采用自身对照病例系列分析评估接种与IMID发作的关联,观察期至接种前6个月和接种后6个月。
- 自身对照病例系列观察期分为接种前14天诱导期、接种后90天暴露期和其余非暴露期。
- 共纳入32 277例患者,其中类风湿关节炎14 151例、IBD 13 631例、中轴型脊柱关节炎3804例、SLE 691例。
主要发现
- 总体57%接种了肺炎球菌疫苗。
- 45岁以下者接种率为32%,IBD患者为42%,无其他接种指征者为46%。
- 疫苗安全性研究中,因关节痛、自身免疫风湿病发作和IBD发作而进行初级保健咨询的接种患者分别纳入1067例、935例和451例。
- 暴露期内接种与关节痛初级保健咨询的发病_rate比为0.95(95%CI 0.83-1.09)。
- 暴露期内接种与自身免疫风湿病发作初级保健咨询的发病_rate比为1.05(95%CI 0.92-1.19),与IBD发作初级保健咨询的发病_rate比为0.83(95%CI 0.65-1.06)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The uptake and safety of pneumococcal vaccination in people with immune-mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK-wide pneumococcal vaccine uptake in adults with IMIDs and explored the association between vaccination and IMID flare. METHODS: Adults with IMIDs diagnosed on or before 1 September 2018, prescribed steroid-sparing drugs within the last 12 months and contributing data to the Clinical Practice Research Datalink Gold, were included. Vaccine uptake was assessed using a cross-sectional study design. Self-controlled case series analysis investigated the association between pneumococcal vaccination and IMID flare. The self-controlled case series observation period was up to 6 months before and after pneumococcal vaccination. This was partitioned into a 14-day pre-vaccination induction, 90 days post-vaccination exposed and the remaining unexposed periods. RESULTS: We included 32 277 patients, 14 151 with RA, 13 631 with IBD, 3804 with axial SpA and 691 with SLE. Overall, 57% were vaccinated against pneumococcus. Vaccine uptake was lower in those younger than 45 years old (32%), with IBD (42%) and without additional indication(s) for vaccination (46%). In the vaccine safety study, data for 1067, 935 and 451 vaccinated patients with primary-care consultations for joint pain, autoimmune rheumatic disease flare and IBD flare, respectively, were included. Vaccination against pneumococcal pneumonia was not associated with primary-care consultations for joint pain, autoimmune rheumatic disease flare and IBD flare in the exposed period, with incidence rate ratios (95% CI) 0.95 (0.83-1.09), 1.05 (0.92-1.19) and 0.83 (0.65-1.06), respectively. CONCLUSION: Uptake of pneumococcal vaccination in UK patients with IMIDs was suboptimal. Vaccination against pneumococcal disease was not associated with IMID flare.
引用
- Nakafero G, Grainge MJ, Card T, et al. Uptake and safety of pneumococcal vaccination in adults with immune-mediated inflammatory diseases: a UK wide observational study. Rheumatology (Oxford). 2025. PMID: 38479823. doi:10.1093/rheumatology/keae160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。